Effects of the angiotensin II type 1 receptor antagonist telmisartan on monocyte adhesion and activation in patients with essential hypertension.

What Was Tested

Researchers studied Angiotensin II Type 1 Receptor Blockers in this clinical trial publication.

To characterize monocyte activation the researchers assessed the expression of activity-related cell surface markers that are also involved in monocyte adhesion to endothelial cells, such as CD11a/b and CD54, as well as the chemokine receptors CCR1, CCR2 and CCR5 before and after telmisartan therapy using flow cytometry.

Who Took Part

The abstract describes 20 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Monocytes of 20 hypertensive patients and 20 normotensive controls were isolated by density gradient centrifugation and Dynabeads, and the monocyte adhesion to human aortic endothelial cell monolayers was measured by adhesion assays.

What Was Measured

To characterize monocyte activation the researchers assessed the expression of activity-related cell surface markers that are also involved in monocyte adhesion to endothelial cells, such as CD11a/b and CD54, as well as the chemokine receptors CCR1, CCR2 and CCR5 before and after telmisartan therapy using flow cytometry.

The subject headings attached to it are Angiotensin II Type 1 Receptor Blockers, B7-1 Antigen, B7-2 Antigen, Benzimidazoles, Benzoates, CD11a Antigen and CD11b Antigen.

What This Means in Plain Language

This is a clinical trial of Angiotensin II Type 1 Receptor Blockers in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2007 (Hypertension research : official journal of the Japanese Society of Hypertension), a journal based in England.

More context: all human trials.